KEAP1 and neoplasm: In recent published in vivo studies, FBXW7 and KEAP1 were suggested to confer immune checkpoint blockade by alternating tumor microenvironment instead of directly modifying the tumor, through the way of decreasing T-cell infiltration and downregulating IFN-γ signaling, respectively (55, 56).